Literature DB >> 20467329

Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation.

Achim Temme1, Kathrin D Geiger, Ralf Wiedemuth, Katharina Conseur, Torsten Pietsch, Jörg Felsberg, Guido Reifenberger, Masaaki Tatsuka, Christian Hagel, Manfred Westphal, Hilmar Berger, Matthias Simon, Michael Weller, Gabriele Schackert.   

Abstract

Giant cell glioblastoma (gcGB), a subtype of GB, is characterized by the presence of numerous multinucleated giant cells. The prognosis for gcGB is poor, but it may have a better clinical outcome compared with classic GB. The molecular alterations that lead to the multinucleated cell phenotype of gcGB have not been elucidated. Giant cell GB has a higher frequency of the tumor suppressor protein p53 mutations than GB, however, and a role for the mitotic Aurora B kinase has been suggested. We analyzed Aurora B expression in gcGB (n = 28) and GB (n = 54) patient tumor samples by immunohistochemistry; 17 gcGB and 22 GB samples were analyzed at the DNA and mRNA levels. No mutations in the Aurora B gene (AURKB) were found, but its mRNA and protein levels were significantly higher in gcGB than in GB. Fifty-nine percent of gcGB samples but only 18% of the GB samples showed p53 mutations. Ectopic overexpression of Aurora B induced a significant increase inthe proportion of multinucleated cells in p53 mutant U373-MG, but not in p53 wild-type U87-MG, glioma cells. RNAi of p53 in U87-MG cells led to an increase in the fraction of multinucleated cells that was further augmented by ectopic overexpression of Aurora B. These results suggest that loss of p53 function and dysregulated Aurora B protein levels might represent factors that drive the development of multinucleated cells in gcGB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20467329     DOI: 10.1097/NEN.0b013e3181e4c06e

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  14 in total

1.  Regulation of AURKC expression by CpG island methylation in human cancer cells.

Authors:  Satoshi Fujii; Vibhuti Srivastava; Apurva Hegde; Yutaka Kondo; Lanlan Shen; Koyu Hoshino; Yvette Gonzalez; Jin Wang; Kaori Sasai; Xiaotu Ma; Hiroshi Katayama; Marcos R Estecio; Stanley R Hamilton; Ignacio Wistuba; Jean-Pierre J Issa; Subrata Sen
Journal:  Tumour Biol       Date:  2015-05-20

2.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Authors:  Nadja Müller; Susanne Michen; Stefanie Tietze; Katrin Töpfer; Alexander Schulte; Katrin Lamszus; Marc Schmitz; Gabriele Schackert; Ira Pastan; Achim Temme
Journal:  J Immunother       Date:  2015-06       Impact factor: 4.456

3.  Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.

Authors:  Zhenjiang Zhao; Guoguo Jin; Ke Yao; Kangdong Liu; Fangfang Liu; Hanyong Chen; Keke Wang; Dhilli Rao Gorja; Kanamata Reddy; Ann M Bode; Zhiping Guo; Zigang Dong
Journal:  Mol Carcinog       Date:  2019-03-01       Impact factor: 4.784

4.  Roles of p53 and p27(Kip1) in the regulation of neurogenesis in the murine adult subventricular zone.

Authors:  Sara Gil-Perotin; Jeffery D Haines; Jasbir Kaur; Mireya Marin-Husstege; Michael J Spinetta; Kwi-Hye Kim; Maria Duran-Moreno; Timothy Schallert; Frederique Zindy; Martine F Roussel; Jose M Garcia-Verdugo; Patrizia Casaccia
Journal:  Eur J Neurosci       Date:  2011-09-07       Impact factor: 3.386

5.  Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma.

Authors:  Liliana Soroceanu; Lisa Matlaf; Sabeena Khan; Armin Akhavan; Eric Singer; Vladimir Bezrookove; Stacy Decker; Saleena Ghanny; Piotr Hadaczek; Henrik Bengtsson; John Ohlfest; Maria-Gloria Luciani-Torres; Lualhati Harkins; Arie Perry; Hong Guo; Patricia Soteropoulos; Charles S Cobbs
Journal:  Cancer Res       Date:  2015-08-01       Impact factor: 12.701

6.  SOX2-RNAi attenuates S-phase entry and induces RhoA-dependent switch to protease-independent amoeboid migration in human glioma cells.

Authors:  Felix Oppel; Nadja Müller; Gabriele Schackert; Sandy Hendruschk; Daniel Martin; Kathrin D Geiger; Achim Temme
Journal:  Mol Cancer       Date:  2011-11-09       Impact factor: 27.401

7.  ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.

Authors:  Christina Hausmann; Achim Temme; Nils Cordes; Iris Eke
Journal:  Oncotarget       Date:  2015-10-27

8.  Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.

Authors:  Marina Conde; Susanne Michen; Ralf Wiedemuth; Barbara Klink; Evelin Schröck; Gabriele Schackert; Achim Temme
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

9.  Survivin safeguards chromosome numbers and protects from aneuploidy independently from p53.

Authors:  Ralf Wiedemuth; Barbara Klink; Katrin Töpfer; Evelin Schröck; Gabriele Schackert; Masaaki Tatsuka; Achim Temme
Journal:  Mol Cancer       Date:  2014-05-09       Impact factor: 27.401

10.  Giant cells glioblastoma: case report and pathological analysis from this uncommon subtype of glioma.

Authors:  Telmo A B Belsuzarri; João F M Araujo; Aguinaldo P Catanoce; Maick W F Neves; Rodrigo A S Sola; Juliano N Navarro; Leandro G Brito; Nilton R Silva; Luis Otavio C Pontelli; Luiz Gustavo A Mattos; Tiago F Gonçales; Wolnei M Zeviani; Renata M B Marques
Journal:  Rare Tumors       Date:  2015-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.